Výsledky vyhledávání

Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers

Autor: AR Belch, RW Yatscoff, GF Murphy, Linda M. Pilarski

Publikováno v: Leukemia. 12:505-509

The malignant clone in myeloma is not eradicated by chemotherapy. Cyclosporins inhibit drug transport mechanisms, particularly the multidrug transporter p-glycoprotein 170, leading to their use as chemosensitizers. In myeloma, clonotypic blood B cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58139eba7e50ea6bc6a4e5703028e536
https://doi.org/10.1038/sj.leu.2400984

Zobrazit plný text záznamu

Increased circulating colony-stimulating factor-1 in patients with preleukemia, leukemia, and lymphoid malignancies

Autor: A Janowska-Wieczorek, AR Belch, A Jacobs, D Bowen, RA Padua, E Paietta, ER Stanley

Publikováno v: Blood. 77:1796-1803

Recently, several malignant cell types have been reported to express colony-stimulating factor-1 (CSF-1) transcripts; however, the clinical significance of CSF-1 in malignancy has not been investigated. Using a CSF-1 radioimmunoassay, we surveyed con

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3e70333aafbf0138cf94242f7028f82b
https://doi.org/10.1182/blood.v77.8.1796.bloodjournal7781796

Zobrazit plný text záznamu

A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction

Autor: Agnieszka Szczepek, Seeberger K, Wizniak J, Mj, Mant, Ar, Belch, Lm, Pilarski

Publikováno v: Europe PubMed Central

In multiple myeloma (MM), the VDJ rearrangement of the immunoglobulin heavy chain expressed by MM plasma cells provides a unique clonotypic marker. Although clonotypic MM cells have been found in the circulation, their number has been controversial.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::ccc99d1ed9c91b4b45b62ff24bae5475
http://europepmc.org/abstract/med/9763569

Zobrazit plný text záznamu

In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease

Autor: Lm, Pilarski, Nv, Giannakopoulos, Agnieszka Szczepek, Am, Masellis, Mj, Mant, Ar, Belch

Publikováno v: Europe PubMed Central

DNA aneuploidy characterizes a proportion of malignant bone marrow (BM)-localized plasma cells in multiple myeloma (MM). This analysis shows that for most MM patients, circulating clonotypic B cells in MM are also hyperdiploid. Although all normal B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b92f4740eb99320fcbf87a8b377b9aab
http://europepmc.org/abstract/med/10690543

Zobrazit plný text záznamu

Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone

Autor: Sp, Treon, Ja, Mollick, Urashima M, Teoh G, Chauhan D, Atsushi Ogata, Raje N, Jh, Hilgers, Nadler L, Ar, Belch, Lm, Pilarski, Kc, Anderson

Publikováno v: Europe PubMed Central

Monoclonal antibodies (MoAbs) that selectively identify Muc-1 core protein (MoAbs DF3-P, VU-4H5) determinants were used to identify the Muc-1 glycoform present on 7 multiple myeloma (MM) cell lines, 5 MM patient plasma cells, 12 MM patient B cells, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::af9144dca6b314dfe7f62fed68ffed98
http://europepmc.org/abstract/med/9949172

Zobrazit plný text záznamu

CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements

Autor: Agnieszka Szczepek, Pl, Bergsagel, Axelsson L, Cb, Brown, Ar, Belch, Lm, Pilarski

Publikováno v: Europe PubMed Central

Peripheral blood mononuclear cells (PBMC) from patients with multiple myeloma (MM) are here shown to include 23% +/- 2% of CD34+ cells, the majority of which coexpress CD19, as identified by a panel of 17 anti-CD34 antibodies. The expression of CD34

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::3127420632ab4aba5593aaca745895a0
http://europepmc.org/abstract/med/9057669

Zobrazit plný text záznamu

Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma

Autor: Lm, Pilarski, Agnieszka Szczepek, Ar, Belch

Publikováno v: Europe PubMed Central

Although chemotherapy effectively reduces the plasma cell burden in multiple myeloma (MM), the disease recurs. MM includes circulating and bone marrow (BM) localized components. A large majority of circulating CD11b+ MM B cells (81%) express an IgH V

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::fca8f0e99b90ff4b89881d3a6028dc85
http://europepmc.org/abstract/med/9345062

Zobrazit plný text záznamu

Akademický článek

Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial.

Autor: Venner CP; The Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada., LeBlanc R; CIUSSS de l'Est de l'Ile de Montréal, Université de Montréal, Montreal, Quebec, Canada., Sandhu I; The Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada., White D; Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada., Belch AR; The Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada., Reece DE; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Chen C; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Dolan S; University of New Brunswick, Saint John Regional Hospital, Saint John, New Brunswick, Canada., Lalancette M; Hotel Dieu Hospital, Quebec City, Quebec, Canada., Louzada M; London Regional Cancer Centre, University of Western Ontario, London, Ontario, Canada., Kew A; The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada., McCurdy A; The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada., Monteith B; Queen's University, Canadian Cancer Trials Group, Kingston, Ontario, Canada., Reiman T; University of New Brunswick, Saint John Regional Hospital, Saint John, New Brunswick, Canada., McDonald G; Queen's University, Canadian Cancer Trials Group, Kingston, Ontario, Canada., Sherry M; Queen's University, Canadian Cancer Trials Group, Kingston, Ontario, Canada., Gul E; Canadian Myeloma Research Group (formerly the Myeloma Canada Research Network), Vaughan, Ontario, Canada., Chen BE; Queen's University, Canadian Cancer Trials Group, Kingston, Ontario, Canada., Hay AE; Queen's University, Canadian Cancer Trials Group, Kingston, Ontario, Canada.

Publikováno v: American journal of hematology [Am J Hematol] 2021 May 01; Vol. 96 (5), pp. 552-560.

Zobrazit plný text záznamu

Akademický článek

MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells.

Autor: Sanyal R; Department of Biochemistry and Molecular Biology, and Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, Canada., Polyak MJ; Department of Biochemistry and Molecular Biology, and Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, Canada., Zuccolo J; Department of Biochemistry and Molecular Biology, and Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, Canada., Puri M; Department of Biochemistry and Molecular Biology, and Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, Canada., Deng L; Department of Biochemistry and Molecular Biology, and Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, Canada., Roberts L; Department of Biochemistry and Molecular Biology, and Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, Canada., Zuba A; Department of Biochemistry and Molecular Biology, and Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, Canada., Storek J; Departments of Medicine and Oncology, University of Calgary, Calgary, Alberta, Canada., Luider JM; Calgary Laboratory Services, Foothills Medical Centre, Calgary, Alberta, Canada., Sundberg EM; Calgary Laboratory Services, Foothills Medical Centre, Calgary, Alberta, Canada., Mansoor A; Calgary Laboratory Services, Foothills Medical Centre, Calgary, Alberta, Canada.; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada., Baigorri E; Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada., Chu MP; Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada., Belch AR; Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada., Pilarski LM; Department of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada., Deans JP; Department of Biochemistry and Molecular Biology, and Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Alberta, Canada.

Publikováno v: Immunology and cell biology [Immunol Cell Biol] 2017 Aug; Vol. 95 (7), pp. 611-619. Date of Electronic Publication: 2017 Mar 17.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání